Singapore markets closed

Straits Times Index
3,336.59
+13.21(+0.40%)
Nikkei
38,487.90
+433.77(+1.14%)
Hang Seng
18,079.61
-150.58(-0.83%)
FTSE 100
8,275.38
+44.33(+0.54%)
Bitcoin USD
67,722.29
+432.25(+0.64%)
CMC Crypto 200
1,422.04
-6.53(-0.46%)

KRMD Aug 2024 5.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.5000

0.0000

(0.00%)

At close: 09:30AM EDT

Business Wire
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic
MAHWAH, N.J., May 14, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce the signing of a Phase III clinical supply agreement for a novel enzyme replacement therapy to treat a rare endocrinological disease.
Simply Wall St.
It Looks Like KORU Medical Systems, Inc.'s (NASDAQ:KRMD) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights KORU Medical Systems to hold its Annual General Meeting on 9th of May Salary of US$563.1k is part of CEO...
GuruFocus.com
KORU Medical Systems Inc (KRMD) Q1 2024 Earnings Call Transcript Highlights: Record Revenue and ...
Discover how KORU Medical Systems achieved its highest quarterly revenue and is strategically positioning for future growth.